July marks Disability Pride Month, a time to commemorate the passage of the Americans With Disabilities Act and to celebrate the diversity, resilience, and visibility of the disabled community. This ...

The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in ...

In a nationwide, retrospective, population-based cohort study, data from the Swedish MS Registry for 7331 patients were analyzed. The adjusted risk of EDSS milestones 3.0, 4.0, and 6.0 were, ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

THE health problems presented by a disease differ decidedly as they are viewed from the standpoint of the community, and from that of the patient and his physician. The primary method of study is also ...

Please provide your email address to receive an email when new articles are posted on . A study examined the effects of exercise in 3,000 patients with MS for up to 15 years. More physical activity ...

Using eye-tracking -- a technique for recording and analyzing eye movements -- a team has shown that individuals with multiple disabilities can improve their social and emotional skills. Although ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

A new study conducted by researchers from the Corrine Goldsmith Dickinson Center for Multiple Sclerosis at Icahn School of Medicine at Mount Sinai in collaboration with Novartis, the University of ...